Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

Overview

Journal Mayo Clin Proc

Specialty General Medicine

Date 2009 Jul 2

PMID 19567717

Citations 203

Authors

Kurt A Kennel

Matthew T Drake

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates are widely prescribed and highly effective at limiting the bone loss that occurs in many disorders characterized by increased osteoclast-mediated bone resorption, including senile osteoporosis in both men and women, glucocorticoid-associated osteoporosis, and malignancies metastatic to bone. Although they are generally well tolerated, potential adverse effects may limit bisphosphonate use in some patients. Optimal use of bisphosphonates for osteoporosis requires adequate calcium and vitamin D intake before and during therapy. The World Health Organization fracture risk assessment algorithm is currently available to determine absolute fracture risk in patients with low bone mass and is a useful tool for clinicians in identifying patients most likely to benefit from pharmacological intervention to limit fracture risk. This fracture risk estimate may facilitate shared decision making, especially when patients are wary of the rare but serious adverse effects that have recently been described for this class of drugs.

Citing Articles

Acromion and Clavicle Stress Fractures After Reverse Total Shoulder Arthroplasty Reflect Failure to Address Osteoporosis: A Case Report and Literature Review.

Cronin J, Curtis K, Richards B, Hibbard J, Skedros J Cureus. 2025; 17(3):e79993.

PMID: 40041247 PMC: 11876088. DOI: 10.7759/cureus.79993.

sLZIP functions as a key modulator of bone remodeling by regulating the crosstalk between osteoblasts and osteoclasts.

Park S, Kim J, Ko J Exp Mol Med. 2025; .

PMID: 40025167 DOI: 10.1038/s12276-025-01414-3.

Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis-Arbuzov or the Pudovik Reaction.

Szalai Z, Bednarik J, Toth B, Takacs A, Tekula S, Kohidai L Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861154 PMC: 11768586. DOI: 10.3390/ph18010091.

Attributable Risk and Consequences of Bone Mineral Density Deficits in Childhood Cancer Survivors.

Goodenough C, Baedke J, Delaney A, Wilson C, Brinkman T, Im C JAMA Netw Open. 2025; 8(1):e2454069.

PMID: 39792384 PMC: 11724346. DOI: 10.1001/jamanetworkopen.2024.54069.

Naïve Bayes is an interpretable and predictive machine learning algorithm in predicting osteoporotic hip fracture in-hospital mortality compared to other machine learning algorithms.

Wang J PLOS Digit Health. 2025; 4(1):e0000529.

PMID: 39746010 PMC: 11694905. DOI: 10.1371/journal.pdig.0000529.

References

Lenart B, Lorich D, Lane J . Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-6. DOI: 10.1056/NEJMc0707493. View

Wysowski D . Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(1):89-90. DOI: 10.1056/NEJMc0808738. View

Cummings S, Schwartz A, Black D . Alendronate and atrial fibrillation. N Engl J Med. 2007; 356(18):1895-6. DOI: 10.1056/NEJMc076132. View

Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore C . Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2008; 20(2):239-44. DOI: 10.1007/s00198-008-0650-y. View

Greenspan S, Tonino R, Smith M, Petruschke R, Wang L, Yates J . Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002; 77(10):1044-52. DOI: 10.4065/77.10.1044. View

Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F . Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res. 2003; 23(11):649-54. DOI: 10.1089/107999003322558782. View

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

Baim S, Miller P . Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009; 24(4):561-74. DOI: 10.1359/jbmr.090203. View

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

10.

Karam R, Camm J, McClung M . Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007; 357(7):712-3. View

11.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

12.

Abrahamsen B, Eiken P, Eastell R . Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2008; 24(6):1095-102. DOI: 10.1359/jbmr.081247. View

13.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

14.

Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R . Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-99. DOI: 10.1056/NEJMoa030897. View

15.

Whyte M . Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2008; 24(6):1132-4. DOI: 10.1359/jbmr.081253. View

16.

Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Ambrosini M . Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008; 49(11):2156-62. DOI: 10.1080/10428190802483778. View

17.

Khan S, Kanis J, Vasikaran S, Kline W, Matuszewski B, McCloskey E . Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997; 12(10):1700-7. DOI: 10.1359/jbmr.1997.12.10.1700. View

18.

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

19.

Black D, Schwartz A, Ensrud K, Cauley J, Levis S, Quandt S . Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24):2927-38. DOI: 10.1001/jama.296.24.2927. View

20.

Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid I . The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2008; 94(2):538-44. DOI: 10.1210/jc.2008-2241. View